Radiation therapy for uterine cancer

Last medical review:

Radiation therapy uses high-energy rays or particles to destroy cancer cells.

Some people with uterine cancer have radiation therapy. Your healthcare team will use what they know about the cancer and about your health to plan the type and amount of radiation, and when and how it is given.

You may have radiation therapy to:

  • destroy cancer cells left behind after surgery or chemotherapy to reduce the risk that the cancer will come back (recur) (called adjuvant therapy)
  • treat uterine cancer if you can’t have surgery
  • relieve pain or control the symptoms of advanced uterine cancer (called palliative therapy)
  • shrink a tumour before other treatments such as surgery or chemotherapy (called neoadjuvant therapy)

Radiation therapy and chemotherapy may be given during the same time period to treat uterine cancer. This is called chemoradiation. Some chemotherapy drugs can help make radiation work better by making cancer cells more sensitive to radiation. Combining chemotherapy and radiation therapy can be more effective than either treatment on its own.

Types of radiation therapy

The following types of radiation therapy are most commonly used to treat uterine cancer.

External radiation therapy

During external radiation therapy, a machine directs radiation through the skin to the tumour and some of the tissue around it. External radiation therapy is also called external beam radiation therapy.

External radiation therapy may be given on its own or together either with brachytherapy or systemic therapy, or both. Treatment with external radiation therapy is usually given 5 days a week, for 4 to 6 weeks. For advanced-stage uterine cancers, doctors may use a type of external radiation called intensity-modulated radiation therapy.

Intensity-modulated radiation therapy (IMRT) delivers radiation from many different angles to treat the entire tumour. In addition to shaping and aiming the radiation beams, IMRT allows the radiation oncologist to adjust the strength (intensity) of the individual beams. This reduces the dose of radiation reaching nearby normal tissue while allowing a higher dose to be delivered to the tumour. It’s useful for treating tumours in hard-to-reach areas.

Brachytherapy

Brachytherapy is a type of internal radiation therapy. A sealed container of a radioactive substance, called an implant, gets placed right into the tumour or in the area near where the tumour was removed. The radiation kills the cancer cells over time. Brachytherapy can be given on its own or together with either external radiation therapy or systemic therapy, or both.

Brachytherapy for uterine cancer may be given intracavitarily or interstitially. Intracavitary and interstitial brachytherapy are sometimes done at the same time.

Intracavitary brachytherapy gives radiation therapy through a cylinder filled with a radioactive substance (called the applicator) that is inserted into the body through the vagina. The applicator may remain in the vagina or be put into the uterus if you didn’t have a hysterectomy. Intracavitary brachytherapy is also called vaginal brachytherapy or vault brachytherapy.

Intracavitary brachytherapy is the most common type of brachytherapy given for uterine cancer.

Intracavitary brachytherapy may be given as a low-dose rate (LDR) or high-dose rate (HDR) treatment.

LDR brachytherapy delivers a lower dose of radiation over a longer period of time. A single LDR treatment can last between 1 and 4 days, during which the applicator or needles and obturator stay in your body. You will have to stay in the hospital for the duration of the LDR treatment. Most people will only have 1 LDR brachytherapy treatment.

HDR brachytherapy delivers a higher dose of radiation in a short period of time. The applicator or needles and obturator are placed in the vagina at the start and end of each HDR treatment. You usually don’t need to stay in the hospital overnight if you have HDR brachytherapy.

HDR brachytherapy is typically given once a week, for up to 3 weeks.

Interstitial brachytherapy gives radiation therapy through long, thin needles filled with a radioactive substance that are placed in the tissue to be treated. The needles are put into the walls of the uterus through your vulva, perineum (area between the vagina and anus), vaginal walls and other surrounding tissue. Interstitial brachytherapy can give a higher dose of radiation than vaginal brachytherapy. You are most likely to have it for recurrent uterine cancer. Interstitial brachytherapy may also be offered for uterine cancer if:

  • the tumour is very large
  • cancer has spread throughout the pelvis
  • the applicator used for intracavitary brachytherapy doesn’t reach the area that needs treatment

Both intracavitary and interstitial brachytherapy are given under general anesthesia or neuraxial anesthesia.

Side effects of radiation therapy

During radiation therapy, your healthcare team protects healthy cells in the treatment area as much as possible. Side effects of radiation therapy will depend mainly on the size of the area being treated, the specific area or organs being treated, the total dose of radiation, the type of radiation you had and the treatment schedule. Tell your healthcare team if you have side effects that you think are from radiation therapy. The sooner you tell them of any problems, the sooner they can suggest ways to help you deal with them.

These are common side effects of radiation therapy for uterine cancer:

Find out more about radiation therapy

Find out more about radiation therapy and side effects of radiation therapy. To make the decisions that are right for you, ask your healthcare team questions about radiation therapy.

Expert review and references

  • Tien Le, MD, FRCSC, DABOG
  • Alberta Health Services. HDR Brachytherapy for Gynecological Cancer: Radioactive Iridium-192 Temporary Implant. 2024. https://www.albertahealthservices.ca/.
  • Alektiar KM, Abu-Rustum NR, Makker V, et al. Cancer of the uterine body. Devita VT, Lawrence TS, Rosenberg SA, eds. DeVita Hellman and Rosenberg's Cancer: Principles and Practice of Oncology. 12th ed. Philadelphia, PA: Wolters Kluwer; 2023: Kindle version, chapter 50, https://read.amazon.ca/?asin=B0BG3DPT4Q&language=en-CA.
  • American Cancer Society. Radiation Therapy for Endometrial Cancer. 2019. https://www.cancer.org.
  • American Cancer Society. Radiation Therapy for Uterine Sarcomas. 2022. https://www.cancer.org/.
  • American Cancer Society. Treatment Choices for Endometrial Cancer, by Stage. 2022. https://www.cancer.org/.
  • American Cancer Society. Treatment for Uterine Sarcoma, by Type and Stage. 2022. https://www.cancer.org/.
  • Campos SM, del Carmen MG. Therapy for endometrial cancer: radiation, chemotherapy, targeted, immunotherapy and other new and novel agents. Chi D, Berchuck A, Dizon DS, Yashar CM. Principles and Practice of Gynecologic Oncology. 8th ed. Philadelphia, PA: Wolters Kluwer Health; 2025: 5.6:159–179.
  • Cancer Research UK. Radiotherapy for Womb Cancer. 2024. https://www.cancerresearchuk.org/.
  • Dana-Farber Cancer Institute. Interstitial Brachytherapy. https://www.dana-farber.org/. November 06, 2024.
  • Guideline Resource Unit (GURU). Uterine Sarcoma. Edmonton, AB: Alberta Health Services; 2023: Clinical Practice Guideline GYNE-007 Version: 3. ​https://www.albertahealthservices.ca/info/cancerguidelines.aspx​.
  • Hacker NF, Friedlander ML. Uterine cancer. Berek J, Hacker NF. Berek and Hacker's Gynecologic Oncology. 7th ed. Philadelphia, PA: Wolters Kluwer; 2021: 10:371–420.
  • Hamilton CA, Pothuri B, Arend RC, et al. Endometrial cancer: A society of gynecologic oncology evidence-based review and recommendations. Gynecologic Oncology. 2021: 160:817–826.
  • Harkenrider MM. Radiation therapy for uterine corpus mesenchymal tumours. Chi D, Berchuck A, Dizon DS, Yashar CM. Principles and Practice of Gynecologic Oncology. 8th ed. Philadelphia, PA: Wolters Kluwer Health; 2025: 6.6:213–215.
  • Princess Margaret Cancer Centre clinical practice guidelines for gynecologic cancer – endometrial. Princess Margaret Cancer Centre Gynecologic Site Group. Princess Margaret Cancer Program Clinical Practice Guidelines. University Health Network; 2015: Laframboise S. https://www.uhn.ca/PrincessMargaret/Health_Professionals/Programs_Departments/Pages/clinical_practice_guidelines.aspx.
  • Memorial Sloan Kettering Cancer Centre. About Your High Dose Rate (HDR) Intracavitary Brachytherapy for Gynecologic Cancer. 2024. https://www.mskcc.org/.
  • Micher C, Van Horn A. Interstitial brachytherapy for gynecologic cancers. OncoLink. Philadelphia, PA: University of Pennsylvania; 2024. https://www.oncolink.org/.
  • Micher C. Intracavitary brachytherapy for gynecologic cancers – vaginal cylinder. OncoLink. Philadelphia, PA: University of Pennsylvania; 2023. https://www.oncolink.org/.
  • National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Uterine Neoplasms (Version 3.2024). 2024.
  • Odette Cancer Centre. High Dose Rate (HDR) Transperineal Interstitial and Intracavitary Brachytherapy: For Patients with Gynecological Cancers. Toronto, ON: Sunnybrook Health Sciences Centre; https://www.sunnybrook.ca/. November 06, 2024.
  • PDQ Adult Treatment Editorial Board. Endometrial Cancer Treatment (PDQ®)–Health Professional Version. National Cancer Institute; 2024. https://www.cancer.gov/.
  • PDQ Adult Treatment Editorial Board. Uterine Sarcoma Treatment (PDQ®)–Health Professional Version. National Cancer Institute; 2022. https://www.cancer.gov/.

Your trusted source for accurate cancer information

With support from readers like you, we can continue to provide the highest quality cancer information for over 100 types of cancer.

We’re here to ensure easy access to accurate cancer information for you and the millions of people who visit this website every year. But we can’t do it alone.

Every donation helps fund reliable cancer information, compassionate support services and the most promising research. Please give today because every contribution counts. Thank you.

Medical disclaimer

The information that the Canadian Cancer Society provides does not replace your relationship with your doctor. The information is for your general use, so be sure to talk to a qualified healthcare professional before making medical decisions or if you have questions about your health.

We do our best to make sure that the information we provide is accurate and reliable but cannot guarantee that it is error-free or complete.

The Canadian Cancer Society is not responsible for the quality of the information or services provided by other organizations and mentioned on cancer.ca, nor do we endorse any service, product, treatment or therapy.


1-888-939-3333 | cancer.ca | © 2025 Canadian Cancer Society